Jasna Tekavec-Trkanjec

411 total citations
26 papers, 194 citations indexed

About

Jasna Tekavec-Trkanjec is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Rheumatology. According to data from OpenAlex, Jasna Tekavec-Trkanjec has authored 26 papers receiving a total of 194 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Pulmonary and Respiratory Medicine, 13 papers in Physiology and 7 papers in Rheumatology. Recurrent topics in Jasna Tekavec-Trkanjec's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (20 papers), Sarcoidosis and Beryllium Toxicity Research (12 papers) and Eosinophilic Disorders and Syndromes (5 papers). Jasna Tekavec-Trkanjec is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (20 papers), Sarcoidosis and Beryllium Toxicity Research (12 papers) and Eosinophilic Disorders and Syndromes (5 papers). Jasna Tekavec-Trkanjec collaborates with scholars based in Croatia, Czechia and Hungary. Jasna Tekavec-Trkanjec's co-authors include Tatjana Peroš-Golubičić, Martina Šterclová, Martina Vašáková, Nesrin Moğulkoç, Veronika Müller, Karel Hejduk, Katarzyna Lewandowska, Ladislav Dušek, Mordechai R. Kramer and Samy Suissa and has published in prestigious journals such as PLoS ONE, Respiratory Medicine and Drug Safety.

In The Last Decade

Jasna Tekavec-Trkanjec

25 papers receiving 190 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jasna Tekavec-Trkanjec Croatia 9 179 85 37 22 19 26 194
Willis S. Bowman United States 7 221 1.2× 86 1.0× 9 0.2× 21 1.0× 13 0.7× 12 275
Monika Žůrková Czechia 5 136 0.8× 73 0.9× 23 0.6× 28 1.3× 7 0.4× 23 188
Francesco Girelli Italy 5 94 0.5× 35 0.4× 53 1.4× 40 1.8× 9 0.5× 10 144
Theresia Mikolasch United Kingdom 4 139 0.8× 35 0.4× 10 0.3× 21 1.0× 6 0.3× 10 157
Lurdes Planas‐Cerezales Spain 7 154 0.9× 49 0.6× 8 0.2× 14 0.6× 10 0.5× 18 196
W. Ennis James United States 6 145 0.8× 167 2.0× 16 0.4× 36 1.6× 6 0.3× 21 199
Sara Teolato Italy 2 127 0.7× 160 1.9× 18 0.5× 45 2.0× 43 2.3× 3 212
Jessica Lau United States 5 74 0.4× 32 0.4× 54 1.5× 25 1.1× 4 0.2× 6 129
Amy Hajari Case United States 6 180 1.0× 49 0.6× 7 0.2× 10 0.5× 4 0.2× 13 194
Norbert Mülleneisen Germany 7 24 0.1× 53 0.6× 37 1.0× 6 0.3× 14 0.7× 32 227

Countries citing papers authored by Jasna Tekavec-Trkanjec

Since Specialization
Citations

This map shows the geographic impact of Jasna Tekavec-Trkanjec's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jasna Tekavec-Trkanjec with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jasna Tekavec-Trkanjec more than expected).

Fields of papers citing papers by Jasna Tekavec-Trkanjec

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jasna Tekavec-Trkanjec. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jasna Tekavec-Trkanjec. The network helps show where Jasna Tekavec-Trkanjec may publish in the future.

Co-authorship network of co-authors of Jasna Tekavec-Trkanjec

This figure shows the co-authorship network connecting the top 25 collaborators of Jasna Tekavec-Trkanjec. A scholar is included among the top collaborators of Jasna Tekavec-Trkanjec based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jasna Tekavec-Trkanjec. Jasna Tekavec-Trkanjec is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vašáková, Martina, Jakub Gregor, Nesrin Moğulkoç, et al.. (2024). Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study. Respiratory Medicine. 234. 107791–107791. 1 indexed citations
2.
Vražić, Hrvoje, et al.. (2023). Investigating the role of obstructive pulmonary diseases and eosinophil count at admission on all-cause mortality in SARS-CoV-2 patients. Wiener klinische Wochenschrift. 135(9-10). 235–243. 2 indexed citations
3.
Májek, Ondřej, Jakub Gregor, Nesrin Moğulkoç, et al.. (2022). Survival and lung function decline in patients with definite, probable and possible idiopathic pulmonary fibrosis treated with pirfenidone. PLoS ONE. 17(9). e0273854–e0273854. 6 indexed citations
4.
Šterclová, Martina, Nesrin Moğulkoç, Katarzyna Lewandowska, et al.. (2021). Differences in Baseline Characteristics and Access to Treatment of Newly Diagnosed Patients With IPF in the EMPIRE Countries. Frontiers in Medicine. 8. 729203–729203. 8 indexed citations
5.
Vašáková, Martina, Martina Šterclová, Nesrin Moğulkoç, et al.. (2021). Healthy survivor bias in patients with idiopathic pulmonary fibrosis in clinical registries. PA477–PA477. 3 indexed citations
6.
Šterclová, Martina, Nesrin Moğulkoç, Jan Kuś, et al.. (2020). Anticoagulant Use and Bleeding Risk in Central European Patients with Idiopathic Pulmonary Fibrosis (IPF) Treated with Antifibrotic Therapy: Real-World Data from EMPIRE. Drug Safety. 43(10). 971–980. 11 indexed citations
7.
Tran, Tanja, Martina Šterclová, Nesrin Moğulkoç, et al.. (2020). The European MultiPartner IPF registry (EMPIRE): validating long-term prognostic factors in idiopathic pulmonary fibrosis. Respiratory Research. 21(1). 11–11. 42 indexed citations
8.
Moğulkoç, Nesrin, Martina Šterclová, Veronika Müller, et al.. (2018). Does body mass index have prognostic significance for patients with idiopathic pulmonary fibrosis?. PA2210–PA2210. 3 indexed citations
9.
Vašáková, Martina, Martina Šterclová, Nesrin Moğulkoç, et al.. (2018). Real world idiopathic pulmonary fibrosis in the EMPIRE registry. PA2203–PA2203. 4 indexed citations
10.
Šterclová, Martina, Nesrin Moğulkoç, Jan Kuś, et al.. (2018). Bleeding risk in IPF patients treated with different anticoagulants:Real world data from the European MultiPartner IPF Registry (EMPIRE). PA2205–PA2205. 1 indexed citations
11.
Müller, Veronika, Martina Šterclová, Nesrin Moğulkoç, et al.. (2018). Differences in baseline characteristics of newly diagnosed IPF patents in the EMPIRE countries. PA2204–PA2204. 1 indexed citations
12.
Peroš-Golubičić, Tatjana, et al.. (2013). WHOQOL-bREF questionnaire as a measure of quality of life in sarcoidosis.. PubMed. 37(3). 701–6. 11 indexed citations
13.
Peroš-Golubičić, Tatjana, et al.. (2010). Morphometric and DNA image analysis of bronchoalveolar lavage fluid macrophages nuclei in interstitial lung diseases with lymphocytic alveolitis.. PubMed. 34(1). 123–9. 1 indexed citations
14.
Peroš-Golubičić, Tatjana & Jasna Tekavec-Trkanjec. (2008). Diffuse pulmonary ossification: an unusual interstitial lung disease. Current Opinion in Pulmonary Medicine. 14(5). 488–492. 36 indexed citations
15.
16.
Peroš-Golubičić, Tatjana, et al.. (2006). Transbronchial fine needle aspiration cytology in the diagnosis of mediastinal/hilar sarcoidosis. Cytopathology. 18(1). 3–7. 8 indexed citations
17.
Peroš-Golubičić, Tatjana, et al.. (2005). Multiple primary intrathoracic neoplasms: case report and a review of the literature.. PubMed. 72(4). 274–8. 5 indexed citations
18.
Peroš-Golubičić, Tatjana, et al.. (2003). [BOOP-bronchiolitis obliterans organizing pneumonia].. PubMed. 124(8-9). 276–83.
19.
Peroš-Golubičić, Tatjana, et al.. (2003). CORRELATION OF LUNG GALLIUM-67 SCINTIGRAPHY WITH LUNG X-RAY AND PULMONARY FUNCTION TESTS IN PATIENTS WITH SARCOIDOSIS. University of Zagreb University Computing Centre (SRCE). 42(2). 91–99. 1 indexed citations
20.
Peroš-Golubičić, Tatjana, et al.. (2001). Lung lavage neutrophils, neutrophil elastase and albumin in the prognosis of pulmonary sarcoidosis.. PubMed. 25(1). 349–55. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Willis S. Bowman Breakdown of academic impact, for papers by Monika Žůrková Breakdown of academic impact, for papers by Francesco Girelli Breakdown of academic impact, for papers by Theresia Mikolasch Breakdown of academic impact, for papers by Lurdes Planas‐Cerezales Breakdown of academic impact, for papers by W. Ennis James Breakdown of academic impact, for papers by Sara Teolato Breakdown of academic impact, for papers by Jessica Lau Breakdown of academic impact, for papers by Amy Hajari Case Breakdown of academic impact, for papers by Norbert Mülleneisen
Rankless by CCL
2026